Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MH-06: sourced facts only. name: "Among these candidates, MH-06 was found to specifically target and effectively degrade ALOX12 protein." [PMID:42430827]; target: "Among these candidates, MH-06 was found to specifically target and effectively degrade ALOX12 protein." [PMID:42430827]; developer: "Department of Gastroenterology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Suzhou 215001, PR China." [PMID:42430827]; modality: "We further synthesized eight novel PROTAC molecules using linker-free PROTAC technology." [PMID:42430827]; stage: "In the cerulein-induced AP mouse model, MH-06 exerted remarkable therapeutic and preventive effects." [PMID:42430827]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on MH-06.